Gastric Cancer, Version 2.2022

Jaffer A. Ajani; Thomas A. D'Amico; David J. Bentrem; Joseph Chao; David Cooke; Carlos Corvera; Prajnan Das; Peter C. Enzinger; Thomas Enzler; Paul Fanta; Farhood Farjah; Hans Gerdes; Michael K. Gibson; Steven Hochwald; Wayne L. Hofstetter; David H. Ilson; Rajesh N. Keswani; Sunnie Kim; Lawrence R. Kleinberg; Samuel J. Klempner; Jill Lacy; Quan P. Ly; Kristina A. Matkowskyj; Michael McNamara; Mary F. Mulcahy; Darryl Outlaw; Haeseong Park; Kyle A. Perry; Jose Pimiento; George A. Poultsides; Scott Reznik; Robert E. Roses; Vivian E. Strong; Stacey Su; Hanlin L. Wang; Georgia Wiesner; Christopher G. Willett; Danny Yakoub; Harry Yoon; Nicole McMillian; Lenora A. Pluchino

doi:10.6004/jnccn.2022.0008

Gastric Cancer, Version 2.2022

Jaffer A. Ajani, Thomas A. D'Amico, David J. Bentrem, Joseph Chao, David Cooke, Carlos Corvera, Prajnan Das, Peter C. Enzinger, Thomas Enzler, Paul Fanta, Farhood Farjah, Hans Gerdes, Michael K. Gibson, Steven Hochwald, Wayne L. Hofstetter, David H. Ilson, Rajesh N. Keswani, Sunnie Kim, Lawrence R. Kleinberg, Samuel J. KlempnerJill Lacy, Quan P. Ly, Kristina A. Matkowskyj, Michael McNamara, Mary F. Mulcahy, Darryl Outlaw, Haeseong Park, Kyle A. Perry, Jose Pimiento, George A. Poultsides, Scott Reznik, Robert E. Roses, Vivian E. Strong, Stacey Su, Hanlin L. Wang, Georgia Wiesner, Christopher G. Willett, Danny Yakoub, Harry Yoon, Nicole McMillian, Lenora A. Pluchino

Research output: Contribution to journal › Review article › peer-review

874 Scopus citations

Abstract

Gastric cancer is the third leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histologic type. Gastric cancer generally carries a poor prognosis because it is often diagnosed at an advanced stage. Systemic therapy can provide palliation, improved survival, and enhanced quality of life in patients with locally advanced or metastatic disease. The implementation of biomarker testing, especially analysis of HER2 status, microsatellite instability (MSI) status, and the expression of programmed deathligand 1 (PD-L1), has had a significant impact on clinical practice and patient care. Targeted therapies including trastuzumab, nivolumab, and pembrolizumab have produced encouraging results in clinical trials for the treatment of patients with locally advanced or metastatic disease. Palliative management, which may include systemic therapy, chemoradiation, and/or best supportive care, is recommended for all patients with unresectable or metastatic cancer. Multidisciplinary team management is essential for all patients with localized gastric cancer. This selection from the NCCN Guidelines for Gastric Cancer focuses on the management of unresectable locally advanced, recurrent, or metastatic disease.

Original language	English (US)
Pages (from-to)	167-192
Number of pages	26
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	20
Issue number	2
DOIs	https://doi.org/10.6004/jnccn.2022.0008
State	Published - Feb 2022

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2022.0008

Cite this

Ajani, J. A., D'Amico, T. A., Bentrem, D. J., Chao, J., Cooke, D., Corvera, C., Das, P., Enzinger, P. C., Enzler, T., Fanta, P., Farjah, F., Gerdes, H., Gibson, M. K., Hochwald, S., Hofstetter, W. L., Ilson, D. H., Keswani, R. N., Kim, S., Kleinberg, L. R., ... Pluchino, L. A. (2022). Gastric Cancer, Version 2.2022. JNCCN Journal of the National Comprehensive Cancer Network, 20(2), 167-192. https://doi.org/10.6004/jnccn.2022.0008

Ajani, JA, D'Amico, TA, Bentrem, DJ, Chao, J, Cooke, D, Corvera, C, Das, P, Enzinger, PC, Enzler, T, Fanta, P, Farjah, F, Gerdes, H, Gibson, MK, Hochwald, S, Hofstetter, WL, Ilson, DH, Keswani, RN, Kim, S, Kleinberg, LR, Klempner, SJ, Lacy, J, Ly, QP, Matkowskyj, KA, McNamara, M, Mulcahy, MF, Outlaw, D, Park, H, Perry, KA, Pimiento, J, Poultsides, GA, Reznik, S, Roses, RE, Strong, VE, Su, S, Wang, HL, Wiesner, G, Willett, CG, Yakoub, D, Yoon, H, McMillian, N & Pluchino, LA 2022, 'Gastric Cancer, Version 2.2022', JNCCN Journal of the National Comprehensive Cancer Network, vol. 20, no. 2, pp. 167-192. https://doi.org/10.6004/jnccn.2022.0008

@article{10dee76a24b7457b81a8930aa1f93fcf,

title = "Gastric Cancer, Version 2.2022",

abstract = "Gastric cancer is the third leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histologic type. Gastric cancer generally carries a poor prognosis because it is often diagnosed at an advanced stage. Systemic therapy can provide palliation, improved survival, and enhanced quality of life in patients with locally advanced or metastatic disease. The implementation of biomarker testing, especially analysis of HER2 status, microsatellite instability (MSI) status, and the expression of programmed deathligand 1 (PD-L1), has had a significant impact on clinical practice and patient care. Targeted therapies including trastuzumab, nivolumab, and pembrolizumab have produced encouraging results in clinical trials for the treatment of patients with locally advanced or metastatic disease. Palliative management, which may include systemic therapy, chemoradiation, and/or best supportive care, is recommended for all patients with unresectable or metastatic cancer. Multidisciplinary team management is essential for all patients with localized gastric cancer. This selection from the NCCN Guidelines for Gastric Cancer focuses on the management of unresectable locally advanced, recurrent, or metastatic disease.",

author = "Ajani, {Jaffer A.} and D'Amico, {Thomas A.} and Bentrem, {David J.} and Joseph Chao and David Cooke and Carlos Corvera and Prajnan Das and Enzinger, {Peter C.} and Thomas Enzler and Paul Fanta and Farhood Farjah and Hans Gerdes and Gibson, {Michael K.} and Steven Hochwald and Hofstetter, {Wayne L.} and Ilson, {David H.} and Keswani, {Rajesh N.} and Sunnie Kim and Kleinberg, {Lawrence R.} and Klempner, {Samuel J.} and Jill Lacy and Ly, {Quan P.} and Matkowskyj, {Kristina A.} and Michael McNamara and Mulcahy, {Mary F.} and Darryl Outlaw and Haeseong Park and Perry, {Kyle A.} and Jose Pimiento and Poultsides, {George A.} and Scott Reznik and Roses, {Robert E.} and Strong, {Vivian E.} and Stacey Su and Wang, {Hanlin L.} and Georgia Wiesner and Willett, {Christopher G.} and Danny Yakoub and Harry Yoon and Nicole McMillian and Pluchino, {Lenora A.}",

year = "2022",

month = feb,

doi = "10.6004/jnccn.2022.0008",

language = "English (US)",

volume = "20",

pages = "167--192",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Harborside Press",

number = "2",

}

TY - JOUR

T1 - Gastric Cancer, Version 2.2022

AU - Ajani, Jaffer A.

AU - D'Amico, Thomas A.

AU - Bentrem, David J.

AU - Chao, Joseph

AU - Cooke, David

AU - Corvera, Carlos

AU - Das, Prajnan

AU - Enzinger, Peter C.

AU - Enzler, Thomas

AU - Fanta, Paul

AU - Farjah, Farhood

AU - Gerdes, Hans

AU - Gibson, Michael K.

AU - Hochwald, Steven

AU - Hofstetter, Wayne L.

AU - Ilson, David H.

AU - Keswani, Rajesh N.

AU - Kim, Sunnie

AU - Kleinberg, Lawrence R.

AU - Klempner, Samuel J.

AU - Lacy, Jill

AU - Ly, Quan P.

AU - Matkowskyj, Kristina A.

AU - McNamara, Michael

AU - Mulcahy, Mary F.

AU - Outlaw, Darryl

AU - Park, Haeseong

AU - Perry, Kyle A.

AU - Pimiento, Jose

AU - Poultsides, George A.

AU - Reznik, Scott

AU - Roses, Robert E.

AU - Strong, Vivian E.

AU - Su, Stacey

AU - Wang, Hanlin L.

AU - Wiesner, Georgia

AU - Willett, Christopher G.

AU - Yakoub, Danny

AU - Yoon, Harry

AU - McMillian, Nicole

AU - Pluchino, Lenora A.

PY - 2022/2

Y1 - 2022/2

N2 - Gastric cancer is the third leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histologic type. Gastric cancer generally carries a poor prognosis because it is often diagnosed at an advanced stage. Systemic therapy can provide palliation, improved survival, and enhanced quality of life in patients with locally advanced or metastatic disease. The implementation of biomarker testing, especially analysis of HER2 status, microsatellite instability (MSI) status, and the expression of programmed deathligand 1 (PD-L1), has had a significant impact on clinical practice and patient care. Targeted therapies including trastuzumab, nivolumab, and pembrolizumab have produced encouraging results in clinical trials for the treatment of patients with locally advanced or metastatic disease. Palliative management, which may include systemic therapy, chemoradiation, and/or best supportive care, is recommended for all patients with unresectable or metastatic cancer. Multidisciplinary team management is essential for all patients with localized gastric cancer. This selection from the NCCN Guidelines for Gastric Cancer focuses on the management of unresectable locally advanced, recurrent, or metastatic disease.

AB - Gastric cancer is the third leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histologic type. Gastric cancer generally carries a poor prognosis because it is often diagnosed at an advanced stage. Systemic therapy can provide palliation, improved survival, and enhanced quality of life in patients with locally advanced or metastatic disease. The implementation of biomarker testing, especially analysis of HER2 status, microsatellite instability (MSI) status, and the expression of programmed deathligand 1 (PD-L1), has had a significant impact on clinical practice and patient care. Targeted therapies including trastuzumab, nivolumab, and pembrolizumab have produced encouraging results in clinical trials for the treatment of patients with locally advanced or metastatic disease. Palliative management, which may include systemic therapy, chemoradiation, and/or best supportive care, is recommended for all patients with unresectable or metastatic cancer. Multidisciplinary team management is essential for all patients with localized gastric cancer. This selection from the NCCN Guidelines for Gastric Cancer focuses on the management of unresectable locally advanced, recurrent, or metastatic disease.

UR - http://www.scopus.com/inward/record.url?scp=85124286440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85124286440&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2022.0008

DO - 10.6004/jnccn.2022.0008

M3 - Review article

C2 - 35130500

AN - SCOPUS:85124286440

SN - 1540-1405

VL - 20

SP - 167

EP - 192

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 2

ER -

Gastric Cancer, Version 2.2022

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this